First Analysis invests in drug development services company
Bio-Kinetic Clinical Applications is a drug development services company that designs and conducts Phase I clinical studies for branded pharmaceutical, biotechnology, and generic drug companies. The company is known for its outstanding reputation for clinical quality, developing study designs, recruiting and screening study participants, and collecting and reporting clinical data.
First Analysis recently participated in a funding round that will help Bio-Kinetic nearly double its capacity, strengthen its services in areas such as data analytics, and add management depth required to implement its growth plan.
The First Analysis investment team was led by Jim Macdonald. We collaborated on this investment with our frequent co-investor, Argentum Group. CapitalSource Finance LLC provided debt financing.
First Analysis is a leading private growth-equity investor. It has one of the longest records (20 years) in private capital investing. It has invested over $970 million, has created over $1.4 billion in fund liquidations, and has over $180 million in active portfolio investments. First Analysis focuses on its three sectors of expertise: outsourced services, information technology, and chemistry-enabled businesses.
First Analysis invests for expansion and growth in small and mid-size companies with established business models, high internal growth rates, and large-market leadership potential. The firm is typically the lead or sole investor in its portfolio companies, investing up to $10 million, and it has a number of established co-investor relationships.